People infected with the SARS-CoV-2 delta variant have approximately double the risk of hospitalization compared with those infected with the alpha variant, a study of more than 40,000 cases from England between 29 March ...
Aug 28, 2021
1
880
Most symptoms of COVID-19 in hospitalized patients are resolved within 12 months, however, around one half still experience at least one persistent symptom, a study of 1,276 patients from Wuhan, China, published in The Lancet, ...
Aug 26, 2021
0
175
Over the past 30 years, the number of adults (aged 30-79 years) living with hypertension worldwide has doubled—rising from an estimated 331 million women and 317 million men in 1990, to 626 million women and 652 million ...
Aug 25, 2021
0
73
Extreme heat is an increasingly common occurrence worldwide, with heat-related deaths and illnesses also expected to rise. The authors of a new two-paper Series on Heat and Health, published in The Lancet, recommend immediate ...
Aug 20, 2021
0
137
The first large-scale population-based study on the association between the SARS-CoV-2 vaccines and Bell's palsy confirms that the beneficial and protective effects of the vaccines far outweigh the risk of this rare adverse ...
Aug 17, 2021
0
4
Gender differences in societal ageing favour men over women, which suggests that men have better resources to help them cope with the challenges of ageing. The international analysis, published in The Lancet Healthy Longevity ...
Aug 5, 2021
0
2
Not enough progress has been made to address physical inactivity worldwide, with adolescents and people living with disabilities (PLWD) among the least likely populations to have the support needed to meet the World Health ...
Jul 22, 2021
2
1
Four percent of newly diagnosed cancer cases in 2020 may by associated with drinking alcohol, according to a global study published in The Lancet Oncology, leading its authors to call for greater public awareness of the link ...
Jul 14, 2021
0
4
Interim data from a phase 3 trial of a COVID-19 vaccine developed in China (CoronaVac) suggests that two doses offer 83.5% protection against symptomatic COVID-19.
Jul 9, 2021
0
4
Two doses of CoronaVac are safe and provoke a strong antibody response among children and adolescents aged 3-17 years, according to a randomised controlled trial of 550 young people published in The Lancet Infectious Diseases ...
Jun 29, 2021
0
9
